Cargando…

Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data

BACKGROUND: Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO(®) Risk Evaluation and Mitigation Strategy; REMS) due to risk of e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garafola, Svetlana, Shiferaw, Elizabeth, Dev, Vikram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491550/ https://www.ncbi.nlm.nih.gov/pubmed/37280463 http://dx.doi.org/10.1007/s40801-023-00372-4

Ejemplares similares

Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017)

Efficacy of brexanolone in postpartum depression
por: Rodríguez Mercado, C. M.
Publicado: (2023)

Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’
por: Shukla, Ajay Kumar, et al.
Publicado: (2021)

Treating Postpartum Depression: What Do We Know about Brexanolone?
por: Ali, Muneeza, et al.
Publicado: (2021)

Brexanolone, a GABA(A) Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis
por: Salwan, Aaron, et al.
Publicado: (2023)

Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
por: Faden, Justin, et al.
Publicado: (2020)

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making
por: Gerbasi, Margaret E., et al.
Publicado: (2021)

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States
por: Eldar-Lissai, Adi, et al.
Publicado: (2020)

Eight-Year Postmarket Safety Surveillance of Delayed Complications With a Flexible Lip Filler
por: Cohen, Joel L., et al.
Publicado: (2022)

Ten-Year Global Postmarket Safety Surveillance of Delayed Complications With a Flexible Cheek Filler
por: Cohen, Joel L., et al.
Publicado: (2022)

Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy
por: Reddy, Doodipala Samba, et al.
Publicado: (2023)

Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways
por: Balan, Irina, et al.
Publicado: (2023)

Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data
por: Gozzo, Lucia, et al.
Publicado: (2023)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
por: Kim, Hyun Ok, et al.
Publicado: (2013)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

Descriptive analysis of postmarket surveillance data for hip implants
por: Pane, Josep, et al.
Publicado: (2020)

Brexanolone as adjunctive therapy in super‐refractory status epilepticus
por: Rosenthal, Eric S., et al.
Publicado: (2017)

Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression
por: Cooper, Miranda C., et al.
Publicado: (2019)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan
por: NISHIKAWA, Ryo, et al.
Publicado: (2021)

Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children
por: Green, Jody L., et al.
Publicado: (2018)

Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience
por: Lüscher, Bernhard, et al.
Publicado: (2019)

Factors associated with postpartum depression among adolescents in Uganda
por: Atuhaire, Catherine, et al.
Publicado: (2018)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data
por: Kawamura, Takahisa, et al.
Publicado: (2018)

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
por: Wollmer, M. Axel, et al.
Publicado: (2021)

Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases
por: Li, Xue-Lin, et al.
Publicado: (2015)

Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan
por: Kondo, Hideyuki, et al.
Publicado: (2021)

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
por: Yuan, Jinyi, et al.
Publicado: (2022)

Single Center Analysis of Japanese Homecoming Delivery and Postpartum Depression
por: Suzuki, Shunji
Publicado: (2022)

The Importance of Registries in the Postmarketing Surveillance of Surgical Meshes
por: Köckerling, Ferdinand, et al.
Publicado: (2018)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

EU postmarket surveillance plans for medical devices
por: Pane, Josep, et al.
Publicado: (2019)

Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression
por: Kato, Masaki, et al.
Publicado: (2015)

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites
por: Makunts, Tigran, et al.
Publicado: (2020)

Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception
por: Singh, Tina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oq36ileei8ve4h9h0aasnncn9r